Gastric cancer (GC) is a major health concern in many countries. GC is a heterogeneous
disease stratified by histopathological differences. However, these variations are not used to …

The past few decades have witnessed the rise of immunotherapy for Gastrointestinal (GI)
tract cancers. The role of immune checkpoint inhibitors (ICIs), particularly programmed death …

Simple Summary DNA release from tumour cells (call circulating tumour DNA) into the blood
stream can be found in patients with gastric cancer through a blood test call a liquid biopsy …

Simple Summary Gastric cancer is the fifth most common tumor worldwide. In the past
couple of decades, there have been many advancements toward earlier detection and better …

In the search for the ideal model of tumours, the use of three-dimensional in vitro models is
advancing rapidly. These are intended to mimic the in vivo properties of the tumours which …

Esophageal cancer is a prevalent tumor of the digestive tract worldwide. The detection rate
of early-stage esophageal cancer is very low, and most patients are diagnosed with …

Simple Summary During the last several years, gastric cancer has been extensively studied
on the molecular level and distinct molecular subtypes have been defined accordingly …

Purpose: The multi-kinase inhibitor (mKi) regorafenib has demonstrated efficacy in
chemorefractory patients with metastatic colorectal cancer (mCRC). However, lack of …

Simple Summary We present an exhaustive review of the literature that has evaluated the
role of ctDNA analysis in upper gastrointestinal tumors, including gastroesophageal …

PURPOSE Subset analyses from phase III evaluation of epidermal growth factor receptor
inhibition (EGFRi) suggest improved outcomes in patients with EGFR-amplified …